Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeEXECUTIVESWilliam Starling Joins the Accumed Radial Board of Directors

William Starling Joins the Accumed Radial Board of Directors

William Starling is a Renowned entrepreneur and Venture Capitalist

Accumed Radial is pleased to announce renowned entrepreneur and venture capitalist William (Bill) N. Starling has become an investor and joined the Accumed Radial Board of Directors.

William Starling’s Background

William Starling is managing Director of Synergy Life Science Partners, LP, a $143 million Venture Capital Partnership and Chief Executive Officer of Synecor, LLC (Synecor), a business generator of new Life Science companies based in Research Triangle Park (RTP), North Carolina. In addition to and among William Starling’s many achievements, Starling was a co-founder of Ventritex, which was later acquired by St. Jude/Abbott after the completion of its IPO. He was on the founding team of Advanced Cardiovascular Systems, which was acquired by Lilly/Guidant/Abbott, and was former President & CEO of Cardiac Pathways, which was acquired by Boston Scientific following the completion of its IPO. He has raised over $280 million in private and public capital. The startup companies he co-founded represent over $4 billion in annual revenues today.

Chairman of the Board Remarks

“Accumed Radial Systems warmly welcomes Bill Starling to our Board of Directors,” said Patrick O’Neill, Chairman of the Board. “Bill is a pioneer in helping companies like Accumed Radial, significantly improve the human condition through advances in the treatment of heart disease. Bill’s wisdom and guidance will be immensely helpful to our company.”

William O’Neill, Founder of Accumed Radial, said “As a cardiology pioneer, I am particularly honored to have one of the founders of the cardiology device industry joining the Accumed Radial Board. Bill Starling’s vast knowledge and insight into this industry is a huge asset to Accumed Radial as we develop new, useful, innovative cardiac devices.”

Starling’s Replies

“I am very pleased to join the Accumed Radial team as an investor and Board member,” said William Starling. “Dr. William O’Neill’s personal contributions to the interventional cardiology/structural heart field are second to none and I am looking forward to helping Accumed Radial as we develop and commercialize more novel technologies for today’s and tomorrow’s cardiology marketplace.”

See other industry executives on the move here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy